Literature DB >> 2401730

Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma.

S K Juneja1, M M Wolf, I A Cooper.   

Abstract

A study of 260 patients with non-Hodgkin's lymphoma (NHL) who underwent bilateral bone marrow biopsy at initial diagnosis showed marrow disease in 99 (38%) cases. The highest incidence of disease (83%) was seen in small lymphocytic lymphoma (SLL) and the lowest (19%) in diffuse large cell lymphoma (DLCL). Among cases with positive marrows, disease was bilateral in all 15 cases of SLL but in only 10 of 20 (50%) of the DLCL cases. In 30 of 99 (30%) positive marrows disease was unilateral. Follicular lymphomas were strongly associated with a paratrabecular pattern, with 40 of 45 positive cases showing this. Discordant histology was seen in six of 20 positive cases of DLCL and two of 37 positive cases of follicular small cleaved cell lymphomas (FSCCL). A bone marrow aspirate was positive in only 56 of the 99 (57%) cases. Peripheral blood disease was present in 15% of the bone marrow positive cases and in 6% of the cases overall. The incidence of marrow disease varies with the histological subtype of lymphoma. The paratrabecular pattern is associated with follicular lymphoma, and bilateral biopsy specimens increase the positivity rate in most subtypes of NHL.

Entities:  

Mesh:

Year:  1990        PMID: 2401730      PMCID: PMC502641          DOI: 10.1136/jcp.43.8.630

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases.

Authors:  R D Brunning; C D Bloomfield; R W McKenna; L A Peterson
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

2.  Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy.

Authors:  R S Stein; J E Ultmann; G E Byrne; E M Moran; H M Golomb; N Oetzel
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

3.  Incidence cytology, and histopathology of non-Hodgkin's lymphomas in the bone marrow.

Authors:  F Dick; C D Bloomfield; R D Brunning
Journal:  Cancer       Date:  1974-05       Impact factor: 6.860

4.  Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

Authors:  P A Bunn; P S Schein; P M Banks; V T DeVita
Journal:  Blood       Date:  1976-01       Impact factor: 22.113

5.  Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies.

Authors:  B S Coller; B A Chabner; H R Gralnick
Journal:  Am J Hematol       Date:  1977       Impact factor: 10.047

6.  Cytogenetic and histologic correlations in malignant lymphoma.

Authors:  P R Koduru; D A Filippa; M E Richardson; S C Jhanwar; S R Chaganti; B Koziner; B D Clarkson; P H Lieberman; R S Chaganti
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

7.  Nodular lymphoma: bone marrow and blood manifestations.

Authors:  R W McKenna; C D Bloomfield; R D Brunning
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

8.  Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations.

Authors:  S E Come; E S Jaffe; J C Andersen; R B Mann; B L Johnson; V T DeVita; R C Young
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

9.  Circulating lymphoma cells in patients with B & T non-Hodgkin's lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement.

Authors:  M Brada; S Mizutani; H Molgaard; J P Sloane; J Treleaven; A Horwich; M J Peckham
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  9 in total
  21 in total

1.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Bone marrow biopsy in non-Hodgkin's lymphoma.

Authors:  S Roath; A G Smith; D Choudhury
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

3.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

4.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

5.  The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy.

Authors:  G Cheng
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

6.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

7.  Bone marrow trephine biopsy.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

8.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

Review 9.  A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination.

Authors:  Roger S Riley; Thomas F Hogan; Dawn R Pavot; Robert Forysthe; Davis Massey; Eileen Smith; Lou Wright; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

10.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.